Drug Profile
Custirsen
Alternative Names: Custirsen-sodium; ISIS 112989; OGX-011; TV-1011Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of British Columbia
- Developer OncoGenex Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides; Thionucleotides
- Mechanism of Action Clusterin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
Most Recent Events
- 23 Feb 2017 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in Canada (IV)
- 23 Feb 2017 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (IV)
- 16 Nov 2016 Discontinued - Phase-I for Solid tumours (Combination therapy) in USA (IV)